Clinical Trials Arena on MSN
ESMO 2025: Eli Lilly’s Verzenio extends survival in high-risk early breast cancer
These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback